CORDIS
EU research results

CORDIS

English EN

A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Project information

Grant agreement ID: 880194

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    30 June 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 3 979 000

  • EU contribution

    € 2 785 300

Coordinated by:

MAXIVAX SA

Switzerland

Project description

English EN

Experimental vaccine for the treatment of Chordoma and head and neck cancer

The head and neck group of cancers includes diseases involving the head and neck, including mouth, throat and salivary glands, with 650 000 new cases annually. Chordoma is a rare cancer of the skull base and the spine. Currently, there are no approved drugs for chordoma treatment. Biotech company MaxiVAX developed a cancer vaccine comprising an immune boost agent released in situ by an engineered cell line and cancer autologous cells providing antigens. A Phase I trial with 25 patients with an advanced stage of cancer showed encouraging efficacy data and safety profile of the treatment. The current EU-funded MaxONCO project Phase II clinical trial will evaluate this vaccine in 45 patients with head and neck cancer and in chordoma patients. The chordoma trial will be conducted in the EU and USA as an Investigational New Drug programme that allows fast-track marketing of the drug in case of successful trial results.

Coordinator

MAXIVAX SA

Address

Rue De Latheenee 24
1206 Geneva

Switzerland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 2 785 300

Project information

Grant agreement ID: 880194

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    30 June 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 3 979 000

  • EU contribution

    € 2 785 300

Coordinated by:

MAXIVAX SA

Switzerland